{"id":"aprepitant-plus-olanzapine","safety":{"commonSideEffects":[{"rate":null,"effect":"Somnolence"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Weight gain"}]},"_chembl":{"chemblId":"CHEMBL3989694","moleculeType":"Small molecule","molecularWeight":"718.83"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aprepitant is a selective neurokinin-1 (NK1) receptor antagonist that crosses the blood-brain barrier to block substance P signaling in chemotherapy-induced nausea and vomiting (CINV) pathways. Olanzapine is an atypical antipsychotic with dopamine D2 and serotonin 5-HT2A antagonism that contributes additional antiemetic activity. The combination targets multiple pathways involved in emesis, particularly for highly emetogenic chemotherapy regimens.","oneSentence":"Aprepitant blocks substance P neurokinin-1 receptors while olanzapine antagonizes dopamine and serotonin receptors, together providing enhanced antiemetic and anti-nausea effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:02:07.040Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy"}]},"trialDetails":[{"nctId":"NCT06952920","phase":"PHASE3","title":"Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer","status":"RECRUITING","sponsor":"Jiuda Zhao","startDate":"2025-08-21","conditions":"Standard Quadruple Antiemetic Therapy, Electroacupuncture, Chemotherapy-induced Gastrointestinal Symptom Cluster","enrollment":388},{"nctId":"NCT03578081","phase":"PHASE3","title":"Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2018-11-20","conditions":"Malignant Neoplasm","enrollment":690},{"nctId":"NCT06200168","phase":"PHASE3","title":"Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer","status":"RECRUITING","sponsor":"Jiuda Zhao","startDate":"2024-01-16","conditions":"Electroacupuncture, Olanzapine-contained Four-drug Antiemetic, Nausea and Vomiting","enrollment":370},{"nctId":"NCT02116530","phase":"PHASE3","title":"Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2014-08-20","conditions":"Hematopoietic/Lymphoid Cancer, Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":401},{"nctId":"NCT02939287","phase":"PHASE3","title":"Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2017-09-23","conditions":"Nausea, Vomiting","enrollment":52},{"nctId":"NCT04437017","phase":"PHASE3","title":"Olanzapine or Dexamethasone, With 5-HT3 RA and NK-1 RA, to Prevent CINV","status":"COMPLETED","sponsor":"Fifth Affiliated Hospital, Sun Yat-Sen University","startDate":"2020-02-03","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":557},{"nctId":"NCT05346731","phase":"PHASE3","title":"Low Dose Olanzapine to the Prophylaxis of Nausea and Vomiting Induced by Chemotherapy in Children and Adolescents","status":"UNKNOWN","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2022-04-01","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":210},{"nctId":"NCT05202275","phase":"PHASE2","title":"The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2020-12-01","conditions":"Nausea, Vomiting, Head and Neck Squamous Cell Carcinoma","enrollment":43},{"nctId":"NCT04075955","phase":"PHASE3","title":"Feasibility of Olanzapine at REduced doSe in hIGHly Emetogenic chemoTherapy","status":"COMPLETED","sponsor":"CR-CSSS Champlain-Charles-Le Moyne","startDate":"2019-04-29","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":30},{"nctId":"NCT03219710","phase":"PHASE3","title":"\"Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)\"","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences","startDate":"2017-07-01","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":240},{"nctId":"NCT03876938","phase":"PHASE3","title":"Olanzapine Versus Aprepitant Based Antiemetic Regimen for High Emetic Chemotherapy","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2019-03-01","conditions":"Antiemetic for Highly Emetogenic Chemotherapy","enrollment":147},{"nctId":"NCT03478605","phase":"PHASE2","title":"Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vomiting (CINV) Prophylaxis","status":"UNKNOWN","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2018-05-25","conditions":"Emesis, Vomiting, Nausea Post Chemotherapy","enrollment":130},{"nctId":"NCT02484911","phase":"PHASE3","title":"Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting","status":"COMPLETED","sponsor":"First Affiliated Hospital of Harbin Medical University","startDate":"2015-05","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":120},{"nctId":"NCT01148264","phase":"PHASE2","title":"Comparison of Olanzapine and Metoclopramide For Treatment Of bReakThrough Emesis","status":"TERMINATED","sponsor":"Karin Jordan","startDate":"2010-07","conditions":"Emesis","enrollment":23}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Emend","Zyprexa"],"phase":"phase_3","status":"active","brandName":"Aprepitant plus Olanzapine","genericName":"Aprepitant plus Olanzapine","companyName":"Rush University Medical Center","companyId":"rush-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aprepitant blocks substance P neurokinin-1 receptors while olanzapine antagonizes dopamine and serotonin receptors, together providing enhanced antiemetic and anti-nausea effects. Used for Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}